Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer

被引：0
|
作者：
Colette A. Whitney
Lauren E. Howard
Stephen J. Freedland
Amanda M. DeHoedt
Christopher L. Amling
William J. Aronson
Matthew R. Cooperberg
Christopher J. Kane
Martha K. Terris
Timothy J. Daskivich
机构：
[1] Durham Veterans Affairs Medical Center,Division of Urology
[2] Duke University School of Medicine,Department of Biostatistics and Bioinformatics
[3] Cedars-Sinai Medical Center,Division of Urology
[4] Oregon Health Sciences University,Department of Urology
[5] West Los Angeles Veterans Affairs Medical Center,Division of Urology
[6] University of California,Department of Urology
[7] University of California,Department of Urology
[8] Charlie Norwood Veterans Affairs Medical Center,Division of Urology
[9] Medical College of Georgia,Division of Urology
来源：
Prostate Cancer and Prostatic Diseases | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：252 / 260
页数：8
相关论文
共 50 条
  • [21] Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).
    Li, Sophia
    Ding, Zhijie
    Lin, Jennifer H.
    Behl, Ajay S.
    Pericone, Chris
    Macomson, Brian
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [22] Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).
    Li, Sophia
    Ding, Zhijie
    Lin, Jennifer H.
    Behl, Ajay S.
    Pericone, Chris
    Macomson, Brian
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Adverse events and costs among non-metastatic castration-resistant prostate cancer patients
    Appukkuttan, Sreevalsa
    Yao, Jianying
    Partridge, Jamie
    Kong, Sheldon X.
    Parkin, Jacqueline
    Freedland, Stephen J.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 145 - 152
  • [24] ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Smith, M. R.
    Antonarakis, E. S.
    Ryan, C. J.
    Berry, W.
    Shore, N. D.
    Liu, G.
    Alumkal, J.
    Higano, C.
    Chow-Maneval, E.
    Rathkopf, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 303 - 303
  • [25] Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management
    Alfredo Tartarone
    Rosa Lerose
    Marina Tartarone
    Medical Oncology, 39
  • [26] Physician preferences for non-metastatic castration-resistant prostate cancer treatment
    Srinivas, Sandy
    Mohamed, Ateesha F.
    Appukkuttan, Sreevalsa
    Botteman, Marc
    Ng, Xinyi
    Joshi, Namita
    Horodniceanu, Erica
    Waldeck, A. Reginald
    Simmons, Stacey J.
    BMC UROLOGY, 2020, 20 (01)
  • [27] ARN-509 in men with high risk non-metastatic castration-resistant prostate cancer
    Smith, M. R.
    Antonarakis, E. S.
    Ryan, C. J.
    Berry, W. R.
    Shore, N. D.
    Liu, G.
    Alumkal, J. J.
    Higano, C. S.
    Maneval, E. Chow
    Rathkopf, D. E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S695 - S695
  • [28] Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
    Lesley J. Scott
    Targeted Oncology, 2022, 17 : 381 - 381
  • [29] Apalutamide: Emerging Therapy for Non-Metastatic Castration-Resistant Prostate Cancer
    Alkhudair, Nora A.
    SAUDI PHARMACEUTICAL JOURNAL, 2019, 27 (03) : 368 - 372
  • [30] The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2019, 13
12345